Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Armata Pharmaceuticals Inc (ARMP)

Armata Pharmaceuticals Inc (ARMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,558
  • Shares Outstanding, K 36,407
  • Annual Sales, $ 5,170 K
  • Annual Income, $ -18,920 K
  • EBIT $ -33 M
  • EBITDA $ -32 M
  • 60-Month Beta 1.24
  • Price/Sales 45.10
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 1
  • High Estimate -0.41
  • Low Estimate -0.41
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -78.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +30.81%
on 12/19/25
7.38 -10.84%
on 11/28/25
-0.64 (-8.86%)
since 11/26/25
3-Month
2.94 +123.81%
on 10/02/25
16.34 -59.73%
on 10/22/25
+3.57 (+118.60%)
since 09/26/25
52-Week
0.90 +632.66%
on 04/09/25
16.34 -59.73%
on 10/22/25
+4.56 (+225.74%)
since 12/26/24

Most Recent Stories

More News
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

LOS ANGELES , Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 6.58 (+2.65%)
Why Armata Pharmaceuticals Skyrocketed 370% Today

Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on the back of groundbreaking mid-stage clinical results for its bacteriophage-based...

ESLA : 1.5400 (-3.14%)
SLP : 18.76 (-2.19%)
ARMP : 6.58 (+2.65%)
BNBX : 2.33 (+0.43%)
IBIO : 1.8900 (+1.07%)
Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025â„¢

LOS ANGELES , Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025â„¢

LOS ANGELES , Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Describes the structure of phage Pa223, which is included in Armata's multi-phage anti- Pseudomonas clinical candidate, AP-PA02

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development...

ARMP : 6.58 (+2.65%)
Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029

ARMP : 6.58 (+2.65%)
New Strong Sell Stocks for May 8th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Armata Pharmaceuticals, Inc. ARMP is a clinical-stage biotechnology company. The Zacks Consensus Estimate for its current year...

COLM : 55.58 (-0.09%)
EFSI : 40.33 (+1.00%)
ARMP : 6.58 (+2.65%)

Business Summary

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including...

See More

Key Turning Points

3rd Resistance Point 6.92
2nd Resistance Point 6.76
1st Resistance Point 6.67
Last Price 6.58
1st Support Level 6.41
2nd Support Level 6.25
3rd Support Level 6.16

See More

52-Week High 16.34
Fibonacci 61.8% 10.44
Fibonacci 50% 8.62
Fibonacci 38.2% 6.80
Last Price 6.58
52-Week Low 0.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar